Dyno, Roche to tackle CNS, liver disease in gene therapy deal worth up to $1.8B

Gene therapies are some of the hottest areas of investment in the biotech world, as are artificial-intelligence-assisted research methodologies, and “Dyno’s right there at the intersection of these two things,” Dyno CEO Eric Kelsic said.

Potential partners have been trying to get in on the action since the company's founding two years ago. Now, Cambridge, Massachusetts-based Dyno unveils its third partnership in the last five months: a pact with Roche's Spark Therapeutics unit to develop central nervous system (CNS) and liver-directed gene therapies.